173 results on '"Wataya-Kaneda M"'
Search Results
2. 562 Brain estrogen levels are associated with gender differences in neuropsychiatric symptoms in mouse model of tuberous sclerosis complex, and sirolimus may contribute to symptom alleviation by controlling neurosteroid levels
3. Topical rapamycin gel was effective in a patient with hypomelanosis of Ito: O-10
4. Partial anhidrosis demonstrated by Q-SART in a patient with a novel mutation in the EDARADD gene
5. 4-(4-hydroroxyphenyl)-2-butanol (rhododendrol) activates autophagy-lysosome pathway in melanocytes: a potential mechanism for skin depigmentation disorder: P113
6. First left–right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex
7. MEG–SAM kurtosis analysis in the localization of the epileptogenic tuber in tuberous sclerosis: A case report
8. CD1a-positive familial cutaneous mastocytosis without germ-line or somatic mutations in c-kit
9. New concept of melanocyte dysfunction in vitiligo vulgaris and tuberous sclerosis complex: role of Th17 cells and therapeutic implication: IS 5
10. A case of Langerhans cell histiocytosis with atypical skin manifestations of bulla, erythema, and depigmentation: OP 10
11. Morphological and ultrastructual assessment for lesional activation of dendritic cells in vitiligo vulgaris: OP 9
12. Cells derived from tuberous sclerosis show a prolonged S phase of the cell cycle and increased apoptosis
13. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity
14. Cutaneous symptoms in a patient with cardiofaciocutaneous syndrome and increased ERK phosphorylation in skin fibroblasts
15. Clinical and genetic features of 20 Japanese patients with vascular-type Ehlers–Danlos syndrome
16. Effects of nonsedative antihistamines on productivity of patients with pruritic skin diseases
17. Sustained transgene expression in vitro and in vivo using an Epstein–Barr virus replicon vector system combined with HVJ liposomes
18. 160 Characteristic distribution of the skin lesions in Tuberous Sclerosis Complex
19. 096 Safety and efficacy of sirolimus gel therapy for patients with TSC involving facial skin lesions in a long-term clinical trial
20. 590 Morphological and functional analysis on M3R mediated sweating in TSC1 k/o mouse
21. 723 Sirolimus delivery to dermis and blood via oral and topical sirolimus formulations in hairless mice
22. 554 Sirolimus gel effectively reduced neurofibromas in neurofibromatosis type 1 in a double-blind, placebo-controlled, randomized clinical trial
23. 1054 Sirolimus gel treatment for tuberous sclerosis complex involving facial angiofibromas and cephalic plaques: A multicenter randomized controlled trial
24. First-genetic analysis of atypical phenotype of pseudoxanthoma elasticum with ocular manifestations in the absence of characteristic skin lesions
25. 184 Sirolimus interferes with the calcium influx to reduce the neuropathic pain in Fabry disease
26. 240 Exploring the niche of dermal neurofibroma in von Recklinghausen’s disease: Evidence for the involvement of polydom
27. Atopic Diathesis in Hypohidrotic/anhidrotic Ectodermal Dysplasia
28. Partial anhidrosis demonstrated by Q-SART in a patient with a novel mutation in the EDARADD gene
29. First‐genetic analysis of atypical phenotype of pseudoxanthoma elasticum with ocular manifestations in the absence of characteristic skin lesions.
30. Effects of nonsedative antihistamines on productivity of patients with pruritic skin diseases
31. The reduction of chromosomal protein P40 in tuberous sclerosis
32. A monoclonal antibody against the nucleus reveals the presence of a common protein in the nuclear envelope, the perichromosomal region, and cytoplasmic vesicles.
33. Differential localization of TGF- -precursor isotypes in psoriatic human skin
34. Novel mutations in 21 patients with tuberous sclerosis complex and variation of tandem splice-acceptor sites in TSC1 exon 14
35. A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex.
36. Differential localization of TGF- -precursor isotypes in normal human skin
37. Calvarial thickening in tuberous sclerosis complex.
38. Sex-based differences in neuropsychiatric symptoms are due to estradiol/ERα-dependent transcriptional regulation via the modulation of steroid levels by sirolimus.
39. Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex.
40. Distribution of shagreen patches and fibrous cephalic plaques in patients with tuberous sclerosis complex: A retrospective cohort study.
41. Distinct Transcriptional Profiles in the Different Phenotypes of Neurofibroma from the Same Subject with Neurofibromatosis 1.
42. Verification of the efficacy of topical sirolimus gel for systemic rare vascular malformations: a pilot study.
43. Tuberous Sclerosis Complex.
44. Pilot study for the treatment of cutaneous neurofibromas in neurofibromatosis type 1 patients using topical sirolimus gel.
45. Validation of the Index for Facial Angiofibromas: A new scoring tool to assess facial angiofibromas in the tuberous sclerosis complex.
46. Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model mice.
47. Author reply to "WNT10A variant and severe scoliosis?"
48. Distribution of hypomelanotic macules in tuberous sclerosis complex: A retrospective cohort study.
49. Familial Michelin tire baby syndrome.
50. Abnormal White Matter Microstructure in the Limbic System Is Associated With Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.